Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

C. H. van der Wouden; A. Cambon-Thomsen; E. Cecchin; K. C. Cheung; C. L. Dávila-Fajardo; V. H. Deneer; V. Dolžan; M. Ingelman-Sundberg; S. Jönsson; M. O. Karlsson; M. Kriek; C. Mitropoulou; G. P. Patrinos; M. Pirmohamed; M. Samwald; E. Schaeffeler; M. Schwab; D. Steinberger; J. Stingl; G. Sunder-Plassmann; G. Toffoli; R. M. Turner; M. H. van Rhenen; J. J. Swen; H. J. Guchelaar

doi:10.1002/cpt.602

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

C. H. van der Wouden, A. Cambon-Thomsen, E. Cecchin, K. C. Cheung, C. L. Dávila-Fajardo, V. H. Deneer, V. Dolžan, M. Ingelman-Sundberg, S. Jönsson, M. O. Karlsson, M. Kriek, C. Mitropoulou, G. P. Patrinos, M. Pirmohamed, M. Samwald, E. Schaeffeler, M. Schwab, D. Steinberger, J. Stingl, G. Sunder-PlassmannG. Toffoli, R. M. Turner, M. H. van Rhenen, J. J. Swen, H. J. Guchelaar^*,

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

78 Citations (Scopus)

Abstract

Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.

Original language	English
Pages (from-to)	341-358
Number of pages	18
Journal	Clinical Pharmacology and Therapeutics
Volume	101
Issue number	3
DOIs	https://doi.org/10.1002/cpt.602
Publication status	Published - 1 Mar 2017
Externally published	Yes

Keywords

Biomarkers
Cost-Benefit Analysis
Electronic Health Records/organization & administration
Europe
Genotype
Humans
Pharmacogenomic Testing/economics
Practice Guidelines as Topic
Precision Medicine/methods
Prospective Studies
Research Design
Treatment Outcome

Access to Document

10.1002/cpt.602

Cite this

van der Wouden, C. H., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Dávila-Fajardo, C. L., Deneer, V. H., Dolžan, V., Ingelman-Sundberg, M., Jönsson, S., Karlsson, M. O., Kriek, M., Mitropoulou, C., Patrinos, G. P., Pirmohamed, M., Samwald, M., Schaeffeler, E., Schwab, M., Steinberger, D., Stingl, J. (2017). Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 101(3), 341-358. https://doi.org/10.1002/cpt.602

@article{85b953ec679a4e82a3635a93d8bd3603,

title = "Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium",

abstract = "Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.",

keywords = "Biomarkers, Cost-Benefit Analysis, Electronic Health Records/organization & administration, Europe, Genotype, Humans, Pharmacogenomic Testing/economics, Practice Guidelines as Topic, Precision Medicine/methods, Prospective Studies, Research Design, Treatment Outcome",

author = "{van der Wouden}, {C. H.} and A. Cambon-Thomsen and E. Cecchin and Cheung, {K. C.} and D{\'a}vila-Fajardo, {C. L.} and Deneer, {V. H.} and V. Dol{\v z}an and M. Ingelman-Sundberg and S. J{\"o}nsson and Karlsson, {M. O.} and M. Kriek and C. Mitropoulou and Patrinos, {G. P.} and M. Pirmohamed and M. Samwald and E. Schaeffeler and M. Schwab and D. Steinberger and J. Stingl and G. Sunder-Plassmann and G. Toffoli and Turner, {R. M.} and {van Rhenen}, {M. H.} and Swen, {J. J.} and Guchelaar, {H. J.}",

note = "{\textcopyright} 2016 American Society for Clinical Pharmacology and Therapeutics.",

year = "2017",

month = mar,

day = "1",

doi = "10.1002/cpt.602",

language = "English",

volume = "101",

pages = "341--358",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "3",

}

van der Wouden, CH, Cambon-Thomsen, A, Cecchin, E, Cheung, KC, Dávila-Fajardo, CL, Deneer, VH, Dolžan, V, Ingelman-Sundberg, M, Jönsson, S, Karlsson, MO, Kriek, M, Mitropoulou, C, Patrinos, GP, Pirmohamed, M, Samwald, M, Schaeffeler, E, Schwab, M, Steinberger, D, Stingl, J, Sunder-Plassmann, G, Toffoli, G, Turner, RM, van Rhenen, MH, Swen, JJ, Guchelaar, HJ 2017, 'Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium', Clinical Pharmacology and Therapeutics, vol. 101, no. 3, pp. 341-358. https://doi.org/10.1002/cpt.602

TY - JOUR

T1 - Implementing Pharmacogenomics in Europe

T2 - Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

AU - van der Wouden, C. H.

AU - Cambon-Thomsen, A.

AU - Cecchin, E.

AU - Cheung, K. C.

AU - Dávila-Fajardo, C. L.

AU - Deneer, V. H.

AU - Dolžan, V.

AU - Ingelman-Sundberg, M.

AU - Jönsson, S.

AU - Karlsson, M. O.

AU - Kriek, M.

AU - Mitropoulou, C.

AU - Patrinos, G. P.

AU - Pirmohamed, M.

AU - Samwald, M.

AU - Schaeffeler, E.

AU - Schwab, M.

AU - Steinberger, D.

AU - Stingl, J.

AU - Sunder-Plassmann, G.

AU - Toffoli, G.

AU - Turner, R. M.

AU - van Rhenen, M. H.

AU - Swen, J. J.

AU - Guchelaar, H. J.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.

AB - Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.

KW - Biomarkers

KW - Cost-Benefit Analysis

KW - Electronic Health Records/organization & administration

KW - Europe

KW - Genotype

KW - Humans

KW - Pharmacogenomic Testing/economics

KW - Practice Guidelines as Topic

KW - Precision Medicine/methods

KW - Prospective Studies

KW - Research Design

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=85012110585&partnerID=8YFLogxK

U2 - 10.1002/cpt.602

DO - 10.1002/cpt.602

M3 - Article

C2 - 28027596

AN - SCOPUS:85012110585

SN - 0009-9236

VL - 101

SP - 341

EP - 358

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602)

Cite this